entertainment -WSS

entertainment

author：knowledge 2025-08-28 06:20:21 - browse：9558

STAT@ASCO 2024 — Chris Boshoff, far right, speaking at a panel with, from left, Matthew Herper of STAT, Ken Keller, Levi Garraway, and Susan Galbraith. Megan Bearder Photography

CHICAGO — The ways clinicians can treat cancers effectively are expanding, partly because technologies today are making old ideas possible, said a panel of oncology industry leaders at STAT@ASCO, STAT’s event here at the annual American Society of Clinical Oncology meeting.

“We’re seeing this expansion in modalities. We have more types of modalities that have arrived or arriving that allow us to exploit targets we’ve known about more than ever before. It’s very exciting,” said Levi Garraway, the chief medical officer of Genentech, at the event. “Things we’ve known about for a long time can be drugged for the first time or in a new, different way.”

That’s led to a surge of new medicines ranging from small molecules to cell therapies, with the potential uses of these treatments expanding into earlier lines of therapy and more cancer types each year. One example the panel singled out is the drug Enhertu, which recently received a tumor-agnostic approval from the Food and Drug Administration.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How one medical school became remarkably diverse
Next article： Awakening the world to the whoosh: A patient's crusade

entertainment

WSS

Why Congress must ban federal programs from using QALYs

Alcohol isn't healthy after all. Will new dietary guidelines reflect that?

Tocagen's brain cancer gene therapy trial continues. Investors worry

Stanford president faces new allegations over 1999 paper

Telehealth startups turn to complex chronic diseases

How to improve immunocompromised access to mAb treatments

focus

entertainment

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

focus

Alkermes shareholders re

'Stay indoors': Escaped wild animal on the loose in Berlin prompts urgent citywide search

ChatGPT in medicine: STAT answers readers' burning questions

Bird flu outbreak in cows is latest avian flu curveball

Tori Bowie and the unacceptable rates of Black maternal death

Use wet bulb globe temperature, not heat index, to protect workers

Continuity nursing helped my family in our darkest PICU moments

Indian pharmaceutical industry in denial over drug

Supreme Court strikes down use of affirmative action

Readout LOUD podcast: What to know about H5N1 bird flu

focus

H5N1 bird flu: what we're starting to learn about infection in cows

Driven by the pandemic, applicants flood public health schools

Google says AlphaFold 3 can map a vast universe of biomolecules

Study: People of West African ancestry at greater risk of cardiac amyloidosis

Awakening the world to the whoosh: A patient's crusade

Use wet bulb globe temperature, not heat index, to protect workers

hotspot

explore

entertainment

leisure time